Suppr超能文献

对拉丁裔和黑人糖尿病患者的代谢功能障碍相关脂肪性肝病进行干预:一项可行性试点研究

Intervening on Metabolic Dysfunction-Associated Steatotic Liver Disease in Latino/a and Black Patients with Diabetes: A Feasibility Pilot.

作者信息

Alexopoulos Anastasia-Stefania, Danus Susanne, Parish Alice, Olsen Maren K, Batch Bryan C, Thacker Connie R, Moylan Cynthia A, Crowley Matthew J

机构信息

Division of Endocrinology, Department of Medicine, Duke University Medical Center, 200 Trent Drive, Baker House, Room 310, Box 3924, Durham, NC, 27710, USA.

Center of Innovation to Accelerate Discovery and Practice Transformation (ADAPT), Durham VA Medical Center, Durham, NC, 27710, USA.

出版信息

Diabetes Ther. 2024 Nov;15(11):2417-2427. doi: 10.1007/s13300-024-01651-1. Epub 2024 Sep 14.

Abstract

INTRODUCTION

Patients with type 2 diabetes (T2D), particularly those from historically marginalized racial and ethnic groups, are at high risk of poor outcomes from metabolic dysfunction-associated steatotic liver disease (MASLD). Evidence-based management (EBM) of MASLD can prevent its progression to cirrhosis and poor outcomes, yet rates of EBM of MASLD are low in T2D.

METHODS

In this pilot study of ten participants, we examined the feasibility and acceptability of a telehealth intervention that delivered EBM of MASLD in Latino/a and Black patients with T2D in the Duke Healthcare System. The intervention included: (a) MASLD education; (b) diet/lifestyle counseling; (c) T2D medication adjustment (i.e., to promote liver health) and (d) ordering of clinically indicated tests and referrals. This 3-month intervention was delivered by an endocrinologist over three virtual study visits. Phone interviews were conducted at study conclusion. We examined rates of recruitment, retention, T2D medication adjustment, and ordering of clinically indicated tests/referrals.

RESULTS

The median age of our cohort was 54.0 (44.0, 59.0); six and four participants self-identified as Latino/a ethnicity and Black race, respectively. Retention rate in this study was 100% (n = 10/10), and all scheduled visits were completed (n = 30/30). Recruitment occurred over one month, and the rate was 25.8% (n = 8/31) by telephone call and 10% (n = 2/20) by electronic health record message. The intervention was highly acceptable based on a median Treatment Acceptability and Preferences score of 4.0 (4.0, 4.0). In exit interviews, all participants reported improved understanding of MASLD and its link to diabetes. All participants received T2D medication adjustment (n = 5/10) and/or clinically indicated testing/referral (n = 10/10) for the purpose of improving MASLD.

CONCLUSIONS

We demonstrated that a telehealth intervention designed to proactively deliver EBM of MASLD was feasible and acceptable in a cohort of Latino/a and Black patients with T2D. Opportunities existed to better align each participants' care with guideline-based care of MASLD.

摘要

引言

2型糖尿病(T2D)患者,尤其是那些来自历史上被边缘化的种族和族裔群体的患者,发生代谢功能障碍相关脂肪性肝病(MASLD)导致不良结局的风险很高。基于证据的MASLD管理(EBM)可以预防其进展为肝硬化和不良结局,但T2D患者中MASLD的EBM率较低。

方法

在这项针对10名参与者的试点研究中,我们检验了一种远程医疗干预措施在杜克医疗系统中为患有T2D的拉丁裔和黑人患者提供MASLD的EBM的可行性和可接受性。该干预措施包括:(a)MASLD教育;(b)饮食/生活方式咨询;(c)T2D药物调整(即促进肝脏健康)以及(d)安排临床指示的检查和转诊。这项为期3个月的干预措施由一名内分泌科医生通过三次虚拟研究访视来实施。在研究结束时进行电话访谈。我们考察了招募率、保留率、T2D药物调整情况以及临床指示检查/转诊的安排情况。

结果

我们队列的中位年龄为54.0岁(44.0,59.0);分别有6名和4名参与者自我认定为拉丁裔和黑人。本研究的保留率为100%(n = 10/10),所有预定访视均已完成(n = 30/30)。招募工作历时一个月,通过电话招募的比率为25.8%(n = 8/31),通过电子健康记录信息招募的比率为10%(n = 2/20)。基于中位治疗可接受性和偏好得分4.0(4.0,4.0),该干预措施具有高度可接受性。在退出访谈中,所有参与者均表示对MASLD及其与糖尿病的联系有了更好的理解。所有参与者均接受了T2D药物调整(n = 5/10)和/或为改善MASLD而安排的临床指示检查/转诊(n = 10/10)。

结论

我们证明了一种旨在主动提供MASLD的EBM的远程医疗干预措施在患有T2D的拉丁裔和黑人患者队列中是可行且可接受的。存在使每位参与者的治疗与基于指南的MASLD护理更好地保持一致的机会。

相似文献

1
Intervening on Metabolic Dysfunction-Associated Steatotic Liver Disease in Latino/a and Black Patients with Diabetes: A Feasibility Pilot.
Diabetes Ther. 2024 Nov;15(11):2417-2427. doi: 10.1007/s13300-024-01651-1. Epub 2024 Sep 14.
4
The impact of metabolic syndrome severity on racial and ethnic disparities in Metabolic Dysfunction-Associated Steatotic Liver Disease.
PLoS One. 2024 Mar 15;19(3):e0299836. doi: 10.1371/journal.pone.0299836. eCollection 2024.
5
Hepatic steatosis and not type 2 diabetes, body mass index, or hepatic fibrosis associates with hyperglucagonemia in individuals with steatotic liver disease.
Am J Physiol Gastrointest Liver Physiol. 2024 Oct 1;327(4):G558-G570. doi: 10.1152/ajpgi.00147.2024. Epub 2024 Aug 6.
9
Epidemiology of metabolic dysfunction-associated steatotic liver disease.
Clin Mol Hepatol. 2025 Feb;31(Suppl):S32-S50. doi: 10.3350/cmh.2024.0431. Epub 2024 Aug 19.

本文引用的文献

2
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2024.
Diabetes Care. 2024 Jan 1;47(Suppl 1):S52-S76. doi: 10.2337/dc24-S004.
3
Implementation of a liver health check in people with type 2 diabetes.
Lancet Gastroenterol Hepatol. 2024 Jan;9(1):83-91. doi: 10.1016/S2468-1253(23)00270-4.
6
Guidelines for Designing and Evaluating Feasibility Pilot Studies.
Med Care. 2022 Jan 1;60(1):95-103. doi: 10.1097/MLR.0000000000001664.
7
Defining comprehensive models of care for NAFLD.
Nat Rev Gastroenterol Hepatol. 2021 Oct;18(10):717-729. doi: 10.1038/s41575-021-00477-7. Epub 2021 Jun 25.
8
EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update.
J Hepatol. 2021 Sep;75(3):659-689. doi: 10.1016/j.jhep.2021.05.025. Epub 2021 Jun 21.
9
Racial Disparities in Diagnosis and Prognosis of Nonalcoholic Fatty Liver Disease.
Clin Liver Dis (Hoboken). 2020 Sep 4;16(2):66-72. doi: 10.1002/cld.948. eCollection 2020 Aug.
10
Effective recruitment for practice-based research: Lessons from the REAL HEALTH-Diabetes Study.
Contemp Clin Trials Commun. 2019 May 1;15:100374. doi: 10.1016/j.conctc.2019.100374. eCollection 2019 Sep.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验